Showing 1371-1380 of 1560 results for "".
- One-Dose J&J COVID-19 Vaccine Meets Criteria as Safe and Effective, FDA Report Findshttps://modernod.com/news/one-dose-jj-covid-19-vaccine-meets-criteria-as-safe-and-effective-fda-report-finds/2478912/Detailed information on a Johnson & Johnson candidate vaccine for COVID-19 raises no safety concerns, according to a report released early Wednesday, according to a USA Today
- Pfizer, Moderna and J&J Tout Supercharged COVID-19 Vaccine Output, Eyeing Nearly 140 Million New Doses by Marchhttps://modernod.com/news/pfizer-moderna-and-jj-tout-supercharged-covid-19-vaccine-output-eyeing-nearly-140-million-new-doses-by-march/2478909/Pfizer, Moderna, and Johnson & Johnson execs say they’re working all the angles on increasing COVID-19 vaccine production and expect to amp up weekly deliveries by tens of millions by the end of March, according to a FiercePharma
- J&J Submits Single-Dose COVID-19 Vaccine for EMA Reviewhttps://modernod.com/news/jj-submits-single-dose-covid-19-vaccine-for-ema-review/2478881/The European Medicines Agency announced Tuesday that it has received a conditional marketing application for Johnson & Johnson’s COVID-19 vaccine candidate Ad26.COV2.S, and that it intends to review the submission under an accelerated timetable. The regulator indicated that the fi
- J&J Files Single-Dose COVID-19 Vaccine for US Emergency Usehttps://modernod.com/news/jj-files-single-dose-covid-19-vaccine-for-us-emergency-use/2478836/Johnson & Johnson submitted a request to the FDA seeking an emergency-use authorization (EUA) for its COVID-19 vaccine candidate Ad26.COV2.S. Paul Stoffels, the company’s chief scientific officer, called the filing “a pivotal step toward reducing the burden of disease for people g
- J&J’s Single-Dose COVID-19 Vaccine 66% Effectivehttps://modernod.com/news/jjs-single-dose-covid-19-vaccine-66-effective/2478814/Johnson & Johnson reported topline results Friday showing that its investigational single-dose vaccine candidate Ad26.COV2.S met all primary and key secondary endpoints of the phase 3 ENSEMBLE study, with an overall efficacy rate of 66% at preventing moderate-to-severe COVID-19, 28 days after
- Center For Sight is the First Practice Worldwide to Offer the OptiBlue IOLhttps://modernod.com/news/center-for-sight-is-the-first-practice-worldwide-to-offer-the-optiblue-iol/2478793/Center For Sight, which operates 14 eye clinics and surgery centers in Southwest Florida, is the first eye care practice to offer the new OptiBlue IOLs (Johnson & Johnson Vision), an advanced intraocular lens technology that filters violet light to improve contrast and clarity for cataract pa
- Early Study Shows J&J’s One-Dose COVID-19 Vaccine Triggered Antibodies in all Participantshttps://modernod.com/news/early-study-shows-jjs-one-dose-covid-19-vaccine-triggered-antibodies-in-all-participants/2478759/Detailed phase 1/2a study findings published in the NEJM on Wednesday showed that all volunteers given Johnson & Johnson’s single-dose coronavirus vaccine Ad26.COV2.S had detectable neutralizing antibodies by day 57. In September, the company reported a preview of the interim results in
- Vaccine Rollout On Track, Expect 300M Doses Through March: Fedshttps://modernod.com/news/vaccine-rollout-on-track-expect-300m-doses-through-march-feds/2478672/If the initial success of the Pfizer-BioNTech rollout continues, and emergency use authorization (EAU) is granted to Moderna and Johnson & Johnson vaccines in development, Operation Warp Speed officials expect to have 300 million doses of COVID-19 vaccines to distribute across the United Stat
- New Survey Finds Critical Need for Education on Cataracts and Modern Treatment Optionshttps://modernod.com/news/new-survey-finds-critical-need-for-education-on-cataracts-and-modern-treatment-options/2478601/Johnson & Johnson Vision announced findings from a new survey that assessed awareness of cataracts among adults around the world. Cataracts are the leading cause of blindness globally,[1] with more than 90% of people developing cataracts by age
- Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-12-month-data-of-investigational-rpgr-gene-therapy-shows-statistically-significant-and-continued-vision-improvement-in-patients-with-xlrp/2478557/The Janssen Pharmaceutical Companies of Johnson & Johnson announced new 12-month data from the ongoing phase 1/2 trial (